These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 9454824)

  • 1. Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma.
    Young PW; Buckle DR; Cantello BC; Chapman H; Clapham JC; Coyle PJ; Haigh D; Hindley RM; Holder JC; Kallender H; Latter AJ; Lawrie KW; Mossakowska D; Murphy GJ; Roxbee Cox L; Smith SA
    J Pharmacol Exp Ther; 1998 Feb; 284(2):751-9. PubMed ID: 9454824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin-sensitizing effect of rosiglitazone (BRL-49653) by regulation of glucose transporters in muscle and fat of Zucker rats.
    Kramer D; Shapiro R; Adler A; Bush E; Rondinone CM
    Metabolism; 2001 Nov; 50(11):1294-300. PubMed ID: 11699047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats.
    Okuno A; Tamemoto H; Tobe K; Ueki K; Mori Y; Iwamoto K; Umesono K; Akanuma Y; Fujiwara T; Horikoshi H; Yazaki Y; Kadowaki T
    J Clin Invest; 1998 Mar; 101(6):1354-61. PubMed ID: 9502777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concentration-dependent stimulatory and inhibitory effect of troglitazone on insulin-induced fatty acid synthase expression and protein kinase B activity in 3T3-L1 adipocytes.
    Barthel A; Krüger KD; Roth RA; Joost HG
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Apr; 365(4):290-5. PubMed ID: 11919653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Euglycemic and hypolipidemic activity of PAT5A: a unique thiazolidinedione with weak peroxisome proliferator activated receptor gamma activity.
    Vikramadithyan RK; Chakrabarti R; Misra P; Premkumar M; Kumar SK; Rao CS; Ghosh A; Reddy KN; Uma C; Rajagopalan R
    Metabolism; 2000 Nov; 49(11):1417-23. PubMed ID: 11092504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo.
    Kubota T; Koshizuka K; Williamson EA; Asou H; Said JW; Holden S; Miyoshi I; Koeffler HP
    Cancer Res; 1998 Aug; 58(15):3344-52. PubMed ID: 9699665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoglycemic action of thiazolidinediones/peroxisome proliferator-activated receptor gamma by inhibition of the c-Jun NH2-terminal kinase pathway.
    Díaz-Delfín J; Morales M; Caelles C
    Diabetes; 2007 Jul; 56(7):1865-71. PubMed ID: 17416798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
    Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
    Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular determinants of FGF-21 activity-synergy and cross-talk with PPARgamma signaling.
    Moyers JS; Shiyanova TL; Mehrbod F; Dunbar JD; Noblitt TW; Otto KA; Reifel-Miller A; Kharitonenkov A
    J Cell Physiol; 2007 Jan; 210(1):1-6. PubMed ID: 17063460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.
    Henke BR; Blanchard SG; Brackeen MF; Brown KK; Cobb JE; Collins JL; Harrington WW; Hashim MA; Hull-Ryde EA; Kaldor I; Kliewer SA; Lake DH; Leesnitzer LM; Lehmann JM; Lenhard JM; Orband-Miller LA; Miller JF; Mook RA; Noble SA; Oliver W; Parks DJ; Plunket KD; Szewczyk JR; Willson TM
    J Med Chem; 1998 Dec; 41(25):5020-36. PubMed ID: 9836620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PAM-1616, a selective peroxisome proliferator-activated receptor γ modulator with preserved anti-diabetic efficacy and reduced adverse effects.
    Kim MK; Chae YN; Choi SH; Moon HS; Son MH; Bae MH; Choi HH; Hur Y; Kim E; Park YH; Park CS; Kim JG; Lim JI; Shin CY
    Eur J Pharmacol; 2011 Jan; 650(2-3):673-81. PubMed ID: 20974124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peroxisome proliferator-activated receptor gamma ligands inhibit estrogen biosynthesis in human breast adipose tissue: possible implications for breast cancer therapy.
    Rubin GL; Zhao Y; Kalus AM; Simpson ER
    Cancer Res; 2000 Mar; 60(6):1604-8. PubMed ID: 10749129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 3. Structure-activity relationship and optimization of the N-aryl substituent.
    Cobb JE; Blanchard SG; Boswell EG; Brown KK; Charifson PS; Cooper JP; Collins JL; Dezube M; Henke BR; Hull-Ryde EA; Lake DH; Lenhard JM; Oliver W; Oplinger J; Pentti M; Parks DJ; Plunket KD; Tong WQ
    J Med Chem; 1998 Dec; 41(25):5055-69. PubMed ID: 9836622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pioglitazone, a specific ligand of the peroxisome proliferator-activated receptor gamma reduces gastric mucosal injury induced by ischaemia/ reperfusion in rat.
    Konturek PC; Brzozowski T; Kania J; Kukharsky V; Bazela K; Kwiecien S; Harsch I; Konturek SJ; Hahn EG
    Scand J Gastroenterol; 2003 May; 38(5):468-76. PubMed ID: 12795455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Halofenate is a selective peroxisome proliferator-activated receptor gamma modulator with antidiabetic activity.
    Allen T; Zhang F; Moodie SA; Clemens LE; Smith A; Gregoire F; Bell A; Muscat GE; Gustafson TA
    Diabetes; 2006 Sep; 55(9):2523-33. PubMed ID: 16936200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention.
    Kim MK; Chae YN; Kim HS; Choi SH; Son MH; Kim SH; Kim JK; Moon HS; Park SK; Shin YA; Kim JG; Lee CH; Lim JI; Shin CY
    Arch Pharm Res; 2009 May; 32(5):721-7. PubMed ID: 19471887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PAR-5359, a well-balanced PPARalpha/gamma dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo.
    Kim MK; Chae YN; Son MH; Kim SH; Kim JK; Moon HS; Park CS; Bae MH; Kim E; Han T; Choi HH; Shin YA; Ahn BN; Lee CH; Lim JI; Shin CY
    Eur J Pharmacol; 2008 Oct; 595(1-3):119-25. PubMed ID: 18727927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MK-0767, a novel dual PPARalpha/gamma agonist, displays robust antihyperglycemic and hypolipidemic activities.
    Doebber TW; Kelly LJ; Zhou G; Meurer R; Biswas C; Li Y; Wu MS; Ippolito MC; Chao YS; Wang PR; Wright SD; Moller DE; Berger JP
    Biochem Biophys Res Commun; 2004 May; 318(2):323-8. PubMed ID: 15120604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repeat treatment of obese mice with BRL 49653, a new potent insulin sensitizer, enhances insulin action in white adipocytes. Association with increased insulin binding and cell-surface GLUT4 as measured by photoaffinity labeling.
    Young PW; Cawthorne MA; Coyle PJ; Holder JC; Holman GD; Kozka IJ; Kirkham DM; Lister CA; Smith SA
    Diabetes; 1995 Sep; 44(9):1087-92. PubMed ID: 7657033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peroxisome proliferator-activated receptor-gamma represses GLUT4 promoter activity in primary adipocytes, and rosiglitazone alleviates this effect.
    Armoni M; Kritz N; Harel C; Bar-Yoseph F; Chen H; Quon MJ; Karnieli E
    J Biol Chem; 2003 Aug; 278(33):30614-23. PubMed ID: 12777391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.